Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
collection:"CTG"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&lookfor=%22Myeloma%22&type=Subject&page=2
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&lookfor=%22Myeloma%22&type=Subject&page=2
Search /vufind/Search2/Results?filter%5B%5D=collection%3A%22CTG%22&lookfor=%22Myeloma%22&type=Subject&page=2
PubPharm (7.806)
11
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma : A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
12
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma : A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
13
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma : An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
14
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment : Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
15
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma : A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Lmmunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Relapsed or Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
16
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) : A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
17
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma : A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
18
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) : MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients With Tumors Wtih mTOR Mutations
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
19
Promoting Diagnosis and Management of AL in Italy (ProDigALIty) : Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
20
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) : MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (Tak-228) in Patients With Tumors With TSC1 or TSC2 Mutations
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
[1]
« Vorheriger
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[781]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
7.806
Aufsätze
7.806
E-Artikel
7.806
E-Ressourcen
Zeitschriftentitel
4.588
WHO International Clinical Trials Registry Plat...
3.218
ClinicalTrials.gov
Thema
7.806
610
6.935
Study Type: Interventional
3.170
Multiple Myeloma
2.647
Neoplasms, Plasma Cell
2.056
Recruitment Status: Not yet recruiting
1.944
Phase: Phase 2
1.671
Phase: Phase 3
1.520
Recruitment Status: Completed
1.376
Recruitment Status: Authorised-recruitment may ...
1.327
Recruitment Status: Recruiting
1.007
Medical Condition: Multiple Myeloma
985
Phase: Phase 1
775
Study Type: Observational
471
Recruitment Status: Active, not recruiting
397
Lymphoma
380
Recruitment Status: Terminated
316
Leukemia
258
Phase: Phase 1/Phase 2
250
Myelodysplastic Syndromes
234
Phase: Phase 1, Phase 2
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4.854
2020-
2.898
2010-2019
54
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
7.676
Englisch
88
Unbestimmt
14
Spanisch
8
Dänisch
8
Französisch
6
Deutsch
2
Tschechisch
2
Galizisch
2
Kinyarwanda
Alle anzeigen ...
weniger ...
Haven't found what you're looking for?
Wird geladen...